<DOC>
	<DOCNO>NCT00019513</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine gemcitabine , fluorouracil , leucovorin treat patient recurrent , refractory , metastatic solid tumor lymphomas .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Recurrent , Refractory , Metastatic Solid Tumors Lymphomas</brief_title>
	<detailed_description>OBJECTIVES : - Determine clinical toxic effect associate administer sequential gemcitabine follow fluorouracil leucovorin calcium patient refractory recurrent metastatic solid tumor lymphomas . - Determine achieve steady-state plasma level gemcitabine fluorouracil patient . - Determine antitumor activity regimen patient . - Determine pharmacodynamics gemcitabine fluorouracil patient . OUTLINE : This dose-escalation study fluorouracil gemcitabine . During first course , patient receive gemcitabine IV 30 minute weekly 2 week follow one week rest . During subsequent course , patient receive gemcitabine follow immediately fluorouracil IV 24 hour weekly 2 week . Patients also receive leucovorin calcium orally day 1 8 IV day 2 9 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Sequential dose escalation fluorouracil follow sequential dose escalation gemcitabine . Cohorts 3-6 patient receive escalate dos fluorouracil gemcitabine maximum tolerate dose ( MTD ) combination determine . The MTD define dose precede 2 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A maximum 108 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer fail standard therapy therapy exists , include , limited : Unresectable primary recurrent solid tumor ( e.g. , colon , pancreatic , lung , esophageal , cholangiocarcinoma ) Metastatic disease Lymphoma prior highdose chemotherapy require autologous allogeneic stem cell rescue No leukemias No CNS metastases primary CNS malignancies No failure prior gemcitabine therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2.0 mg/dL Transaminases le 6 time upper limit normal Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious concurrent medical illness would preclude study No active infection require IV antibiotic HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics More 4 week since prior immunotherapy recover Chemotherapy : See Disease Characteristics More 4 week since prior chemotherapy ( least 6 week mitomycin nitrosoureas ) recover At least 3 month since prior suramin At least 5 week since prior eniluracil ( 8 week prior start fluorouracil ) recover Endocrine therapy : No steroid therapy utilized chronic lymphoma therapy At least 4 week since prior steroidal therapy disease treatment Radiotherapy : At least 2 week since prior radiotherapy 20 % bone marrow At least 4 week since prior radiotherapy 21 % bone marrow Recovered prior radiotherapy Surgery : Recovered prior surgery Other : No concurrent cimetidine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>adult primary cholangiocellular carcinoma</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>cholangiocarcinoma gallbladder</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>cholangiocarcinoma extrahepatic bile duct</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>